At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 7 enrolled
Drug / intervention
IXAZOMIBdrug
Likely dose
IXAZOMIB 4.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma
In Brief
A Phase 1 clinical trial evaluating IXAZOMIB for Advanced Solid Tumors and Lymphoma. Completed, enrolled 7 participants across 1 site.
Detailed Summary
This is a phase 1, 2-part, open-label study in 4 to 6 pharmacokinetic-evaluable participants with advanced solid tumors or lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartMar 2014
Primary CompletionDec 2014
Study CompletionFeb 2016
TodayJul 2026
First PostedOct 1, 2013
Enrollment StartMar 19, 2014
Primary CompletionDec 17, 2014
Study CompletionFeb 9, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.8 years ago
Interventions
IXAZOMIBdrug
Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21. Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity.